Primary Immunodeficiency Disorders News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Global Plasma Protein Therapeutics Market: Segmental Highlights and Table of Content ( 2016 ? 2024) - Digital Journal



Global Plasma Protein Therapeutics Market: Segmental Highlights and Table of Content ( 2016 ? 2024) 
Digital Journal
Since these drugs are found quite efficient in the treatment of primary immunodeficiency diseases, demand from the product segment is likely to continue increasing at a robust pace through the forecast period. By application, use of plasma protein ...

and more » 


First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary ... - Business Wire (press release)



First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary ... 
Business Wire (press release)
WHIM syndrome is a primary immunodeficiency disease (?PID?) caused by genetic mutations in the CXCR4 receptor gene resulting in susceptibility to certain types of infections. WHIM is an abbreviation for the characteristic clinical symptoms of the ...

and more » 


Growing number of Primary Immunodeficiency Diseases Treatment Market 2017-2021 - MilTech



Growing number of Primary Immunodeficiency Diseases Treatment Market 2017-2021 
MilTech
?The Report Global Primary Immunodeficiency Diseases Treatment Market 2017-2021 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. ? MarketResearchReports.biz?. About Primary ...

and more » 


Bellicum Pharma (BLCM) Reports Data Presentation Demonstrating Improved Immune Recovery Following ... - StreetInsider.com



Bellicum Pharma (BLCM) Reports Data Presentation Demonstrating Improved Immune Recovery Following ... 
StreetInsider.com
Investigators evaluated immune recovery and outcomes of 112 pediatric patients who underwent a haplo-HSCT followed by treatment with BPX-501. Children in the study had acute leukemia (n=53), Primary Immune Deficiencies (n=26), erythroid disorders (n=17 ...

 


Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem ... - GlobeNewswire (press release)



Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem ... 
GlobeNewswire (press release)
Investigators evaluated immune recovery and outcomes of 112 pediatric patients who underwent a haplo-HSCT followed by treatment with BPX-501. Children in the study had acute leukemia (n=53), Primary Immune Deficiencies (n=26), erythroid disorders (n=17 ...

and more » 


Arthritis Drug Seen Lowering GvHD Risk - MedPage Today



Arthritis Drug Seen Lowering GvHD Risk 
MedPage Today
As many as half of patients with severe GvHD ultimately die of the immune disorder. Kean's interest in abatacept for GvHD originated with the drug's mechanism of action in RA: inhibition of T-cell activation that sets in motion the cascade of events ...

 


ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Financial Statements and Exhibits - Market Exclusive



Press Telegraph
 
ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Financial Statements and Exhibits 
Market Exclusive
... operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are ...
Comparing ADMA Biologics (NASDAQ:ADMA) and Its Rivals The Ledger Gazette
ADMA Biologics (NASDAQ:ADMA) & Gilead Sciences (GILD) Head ... Dispatch Tribunal
Adma Biologics Inc - ADMA - Stock Price Today - Zacks Zacks Investment Research

all 29 news articles » 


Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune? and ... - GlobeNewswire (press release)



Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune? and ... 
GlobeNewswire (press release)
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today Day 100 ...

and more » 


Bioverativ compass points True North - BioWorld Online



Bioverativ compass points True North 
BioWorld Online
The MAb, aimed at the treatment of cold agglutinin disease (CAgD), was generally well tolerated, rapidly halted hemolysis and improved anemia in six severely anemic primary CAgD patients during a phase Ib trial conducted by True North. Bioverativ ...

and more » 


First Clinical Data for X4P-001-RD Demonstrating Preliminary ... - Business Wire (press release)



Endpoints News
 
First Clinical Data for X4P-001-RD Demonstrating Preliminary ... 
Business Wire (press release)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Dr. David C. Dale, MD will ...
X4 Pharmaceuticals Secures $27 Million in Series B Financing ... Digital Journal

all 4 news articles »